Revolution Medicines (RVMD) Treasury Shares (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Treasury Shares of $5.1 million for Q1 2026, up 33.82% year-over-year from $3.8 million in Q1 2025, and up 32.12% quarter-over-quarter from $3.9 million in Q4 2025.
Revolution Medicines (RVMD) Treasury Shares (2019 - 2026) Analysis & Trends
Revolution Medicines' Treasury Shares history runs 8 years deep, the most recent figure standing at $5.1 million for Q1 2026.
- In Q1 2026, Treasury Shares rose 33.82% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (up 33.82% YoY), while the FY2025 annual figure was $3.9 million, up 36.56% from the prior year.
- Treasury Shares for Q1 2026 stood at $5.1 million, up from $3.9 million in the prior quarter.
- The five-year high for Treasury Shares was $5.1 million in Q1 2026, with the low at $1.1 million in Q1 2022.
- The 5-year median for Treasury Shares is $2.9 million (2024), against an average of $2.7 million.
- The sharpest annual moves came in 2022 and 2025: Treasury Shares surged 223.62% in 2022, then grew 19.76% in 2025.
- Revolution Medicines' Treasury Shares stood at $1.2 million in 2022, then surged by 83.93% to $2.2 million in 2023, then surged by 31.87% to $2.9 million in 2024, then jumped by 36.56% to $3.9 million in 2025, then soared by 32.12% to $5.1 million in 2026.
- Business Quant data shows RVMD's Treasury Shares at $5.1 million in Q1 2026, $3.9 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 48.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.08 Mn |
| Jun 30, 2026 | 5.08 Mn |
| Mar 31, 2026 | 5.14 Mn |
| Mar 31, 2026 | 5.14 Mn |
| Dec 31, 2025 | 3.89 Mn |
| Dec 31, 2025 | 3.89 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Jun 30, 2025 | 3.81 Mn |
| Jun 30, 2025 | 3.81 Mn |
| Mar 31, 2025 | 3.84 Mn |
| Mar 31, 2025 | 3.84 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Mar 31, 2024 | 3.21 Mn |
| Mar 31, 2024 | 3.21 Mn |